Skip to main content
SpringerLink
Log in

Neurologic Complications of Plasma Cell Dyscrasias

  • Chapter
Cancer Neurology In Clinical Practice

Summary

Plasma cell dyscrasias are an uncommon but important cause of neurologic morbidity. The pathophysiology of these disorders is quite varied and ranges from direct effects of cancer on neurologic tissues to remote effects caused by monoclonal antibodies. This chapter discusses these hematologic disorders and their neurologic consequences including monoclonal gammopathy of undetermined significance, multiple myeloma and its rare variants, osteosclerotic myeloma and POEMS syndrome, and primary systemic amyloidosis. While not all of these disorders are classified as malignancies, they all share derivation from a single clone of plasma cells and thus are best discussed as a group. This review gives the clinician a framework for evaluating and treating these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kelly JJ, Jr: Peripheral neuropathies associated with monoclonal proteins: a clinical review. Muscle Nerve 1985;8:138–150.

    Article  PubMed  Google Scholar 

  2. Latov N, Sherman WH, Nemni R et al. Plasma cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral nerve myelin. N Engl J Med 1980;303:618–621.

    PubMed  CAS  Google Scholar 

  3. Kyle RA. Plasma cell dyscrasias. In: Spitell JA, Jr, (ed.). Clinical Medicine. Philadelphia: Harper & Row, 1981:1–35.

    Google Scholar 

  4. Latov NR, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. CRC Crit Rev Neurobiol 1988;3:301–332.

    CAS  Google Scholar 

  5. Katzman JA, Disperienzi A, Kyle RA et al. Elimination of the need for urine studies in the screening algorithm for monocalon gammopathies by using serum immunfixation and free light chain assays. Mayo Clinic Proc 2006;81(12):1575–1578.

    Google Scholar 

  6. Kelly JJ, Jr, Kyle RA, O’Brien PC et al. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981;31:1480–1483.

    PubMed  Google Scholar 

  7. Kyle RA. “Benign” monoclonal gammopathy: A misnomer? JAMA 1984;251:1849–1854.

    Article  PubMed  CAS  Google Scholar 

  8. Kelly JJ, Jr, Kyle RA, Latov N. Polyneuropathis Associated with Plasma Cell Dyscrasias. Boston: Martinus-Nijhoff, 1987.

    Google Scholar 

  9. Latov N, Braun PE, Gross RA et al. Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc Nat Acad Sci 1981;78:7139–7142.

    Article  PubMed  CAS  Google Scholar 

  10. Yu RK, Ariga T. The role of glycosphingolipids in neurological disorders: mechanisms of immune action. Ann NY Acad Sci 1998;19:285–306.

    Article  Google Scholar 

  11. Ilyas AA, Cook SD, Dalakas MC et al. Anti-MAG IgM paraproteins from some patients with polyneuropathy associated with IgM paraproteinemia also react with sulfatide. J Neuroimmunol 1992;37:85–92.

    Article  PubMed  CAS  Google Scholar 

  12. Steck AJ, Murray N, Dellagi K et al. Peripheral neuropathy associated with monoclonal IgM autoantibody. Ann Neurol 1987;22:764–767.

    Article  PubMed  CAS  Google Scholar 

  13. Chassande B, Leger JM, Younes-Chennoufi AB, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 1998;21:55–62.

    Article  PubMed  CAS  Google Scholar 

  14. Kelly JJ, Jr, Adelman LS, Berkman E et al. Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol 1988;45;1355–1359.

    PubMed  Google Scholar 

  15. Kelly JJ, Jr. The electrodiagnostic findings in polyneuropathies associated with IgM monoclonal gammopathies. Muscle Nerve. 1990;13:1113–1117.

    Article  PubMed  Google Scholar 

  16. Latov N, Wokke JHJ, Kelly JJ, Jr. Immunological and infectious diseases of the peripheral nerves. Cambridge: Cambridge University Press, 1997.

    Google Scholar 

  17. Melmed C, Frail DE, Duncan I et al. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin-associated glycoprotein. Neurology 1983;33:1397–1405.

    PubMed  CAS  Google Scholar 

  18. Bain PG, Britton TC, Jenkins IH et al. Tremor associated with benign IgM paraproteinemia. Brain 1996;119:789–799.

    Article  PubMed  Google Scholar 

  19. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994;117:941–947.

    Article  PubMed  Google Scholar 

  20. Kelly JJ. Neurologic disorders in benign and malignant plasma cell dyscrasias. In: Noseworthy JL, (ed.) Neurologic Therapeutics: Principles and Practice, Vol. 2, 2nd ed., London: Martin Dunitz, 2006:1361–1372.

    Google Scholar 

  21. Ellie E, Vital A, Steck A et al. Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological, and pathological findings and response to treatment in 33 cases. J Neurol 1996;243:34–43.

    Article  PubMed  CAS  Google Scholar 

  22. Jacobs JM. Morphological changes at paranodes in IgM paraproteinaemic neuropathy. Microsc Res Tech 1996;34:544–553.

    Article  PubMed  CAS  Google Scholar 

  23. Nemni R, Galassi G, Latov N et al. Polyneuropathy in nonmalignant IgM plasma cell dyscrasia: a morphological study. Ann Neurol 1983;14:43–54.

    Article  PubMed  CAS  Google Scholar 

  24. Levine T, Pestronk A, Florence J et al. Peripheral neuropathies in Waldenström’s macroglobulinaemia. J Neurol Neurosurg Psychiatry. 2006;77:224–228.

    Article  PubMed  CAS  Google Scholar 

  25. Suarez GA, Kelly JJ, Jr. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS. Neurology 1993;43:1304–1308.

    PubMed  CAS  Google Scholar 

  26. Gosselin S, Kyle R, Dyck P. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol 1991;30:54–61.

    Article  PubMed  CAS  Google Scholar 

  27. Simovic D, Gorson KC, Ropper AH. Comparison of IgM-MGUS and IgG-MGUS polyneuropathy. Acta Neurol Scand 1998;97:194–200.

    Article  PubMed  CAS  Google Scholar 

  28. Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol 1993:33;502–506.

    Article  PubMed  Google Scholar 

  29. Notermans NC, Lokhorst HM, Franssen H et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1996;47:1227–1233.

    PubMed  CAS  Google Scholar 

  30. Meucci N, Baldini L, Cappellari A, et al. Anti–myelin–associated antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy. Ann Neurol 1999;46:119–222.

    Article  PubMed  CAS  Google Scholar 

  31. Weiss MD, Dalakas MC, Lauter CJ et al. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemias. J Neuroimmunol 1999;95:174–184.

    Article  PubMed  CAS  Google Scholar 

  32. Dalakas MC, Quarles RH, Farrer RG et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792–795.

    Article  PubMed  CAS  Google Scholar 

  33. Ernerudh JH, Vrethem M, Andersen O et al. Immunochemical and clinic effects of immunosuppressive treatment in monoclonal IgM neuropathy. J Neurolog Neurosurg Psychiatry 1992;55:930–934.

    CAS  Google Scholar 

  34. Nobile-Orazio E, Meucci N, Baldini L et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710–717.

    Article  PubMed  Google Scholar 

  35. Wilson HC, Lunn MP, Schey S et al. Successful treatment of IgM paraporteinemia with fludarabine. J Neurol Neurosurg Psychiatry 1999;66:575–580.

    PubMed  CAS  Google Scholar 

  36. European Federation of Neurological Societies, Peripheral Nerve Society, Hadden RD et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13:809–818.

    Article  PubMed  CAS  Google Scholar 

  37. Sonnett TE, Setter SM, Campbell RK. Pregabalin for the treatment of painful neuropathy. Expert Rev Neurother. 2006;6:1629–1635.

    Article  PubMed  CAS  Google Scholar 

  38. Kelly JJ. Chronic peripheral neuropathy responsive to rituximab. Rev Neurol Dis. 2006;3:78–81.

    PubMed  Google Scholar 

  39. Mariette X, Chastang C, Clavelou P et al. A randomized clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM: the IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1997;63:28–34.

    PubMed  CAS  Google Scholar 

  40. Osby LE, Noring L, Hast R et al. Benign monoclonal gammopathy and peripheral neuropathy. Br J Haematol 1982;51:531–539.

    Article  PubMed  CAS  Google Scholar 

  41. McLeod JG, Walsh JC, Pollard JD. Neuropathies associated with paraproteinemias and dysproteinemias. In: Dyck PJ, Thomas PK, Lambert EH et al. (eds.) Peripheral Neuropathy, 2nd ed. Philadelphia: W.B. Saunders, 1984:1857–1860.

    Google Scholar 

  42. DiTroia A, Carpo M, Meucci N et al. Clinical features and antineural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J Neurol Sci 1999;15:64–71.

    Article  Google Scholar 

  43. Nobile-Orazio E, Casellato C, Di Troia A. Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol (Paris) 2002;158:979–987.

    CAS  Google Scholar 

  44. Simmons Z, Albers JW, Bromberg MB et al. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology. 1993;43:2202–2209.

    PubMed  CAS  Google Scholar 

  45. Vallat JM, Tabaraud F, Sindou P et al. Myelin widenings and MGUS-IgA: an immunoelectron microscopic study. Ann Neurol 2000;47:808–811.

    Article  PubMed  CAS  Google Scholar 

  46. Gorson KC, Ropper AH. Axonal neuropathy associated with monoclonal gammopathy of undetermined significance. J Neurol Neurosurg Psychiatry 1997;63:163–168.

    PubMed  CAS  Google Scholar 

  47. Raskin J, Pritchett YL, Wang F et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346–356.

    Article  PubMed  Google Scholar 

  48. Denier C, Lozeron P, Adams D et al. Multifocal neuropathy due to plasma cell infiltration of peripheral nerves in multiple myeloma. Neurology 2006;28:917–918.

    Article  Google Scholar 

  49. Leifer D, Grabowski T, Simonian N et al. Leptomeningeal myelomatosis presenting with mental status changes and other neurologic findings. Cancer 1992;70:1899–1904.

    Article  PubMed  CAS  Google Scholar 

  50. Roddie P, Collie D, Johnson P. Myelomatous involvement of the dura mater: a rare complication of multiple myeloma. J Clin Pathol 2000;53:398–399.

    Article  PubMed  CAS  Google Scholar 

  51. Wisniewski T, Sisti M, Inhirami G et al. Intracerebral solitary plasmacytoma. Neurosurgery 1990;27:826–829; discussion 829.

    Article  PubMed  CAS  Google Scholar 

  52. Gertz MA, Lacy MQ, Dispenzieri A et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549–555.

    Article  PubMed  CAS  Google Scholar 

  53. Kelly JJ, Jr, Kyle RA, Miles JM et al. The spectrum of peripheral neuropathy in myeloma. Neurology (NY) 1981;31:24–31.

    Google Scholar 

  54. Kyle RA. Clinical aspects of multiple myeloma and related disorders including amyloidosis. Pathol Biol 1999;47:148–157.

    PubMed  CAS  Google Scholar 

  55. Kelly JJ, Jr, Kyle RA, Miles JM et al. Osteosclerotic myeloma and peripheral neuropathy. Neurology (NY) 1983;33:202–210.

    Google Scholar 

  56. Michel JL, Gaucher-Hugel AS, Reynier C et al. POEMS syndrome: imaging of skeletal manifestations, a study of 8 cases. J Radiol 2003;84:393–397.

    PubMed  CAS  Google Scholar 

  57. Lindstrom E, Lindstrom FD. Skeletal scintigraphy with technetium diphosphonate in multiple myeloma: a comparison with skeletal X-ray. Acta Med Scand 1980;208:289–291.

    PubMed  CAS  Google Scholar 

  58. Tamir R, Glanz I, Lubin E et al. Comparison of the sensitivity of 99mTc–methyl diphosphonate bone scan with the skeletal X-ray survey in multiple myeloma. Acta Haematol 1983;69:236–242.

    PubMed  CAS  Google Scholar 

  59. Gherardi RK, Authier FJ, Belec L. Les cytokines pro-inflammatoires: une cle pathogenique du syndrome POEMS. Rev Neurologique 1996;64:809–812.

    Google Scholar 

  60. Adams D, Said G. Ultrastructural characterisation of the M protein in nerve biopsy of patients with POEMS syndrome. J Neurol Neurosurg Psychiatry 1998;64:809–812.

    PubMed  CAS  Google Scholar 

  61. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029–1039.

    PubMed  CAS  Google Scholar 

  62. Scarlato M, Previtali SC, Carpo M et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 2005;128:1911–1920.

    Article  PubMed  Google Scholar 

  63. Donofrio PD, Albers JW, Greenberg HS et al. Peripheral neuropathy in osteosclerotic myeloma: clinical and electrodiagnostic improvement with chemotherapy. Muscle Nerve 1984;7:137–141.

    Article  PubMed  CAS  Google Scholar 

  64. Kuwabara S, Hattori T, Shimoe Y et al. Long-term melphalan–prednisolone chemotherapy for POEMS syndrome. J Neurol Neurosurg Psychiatry 1997;63:385–387.

    PubMed  CAS  Google Scholar 

  65. Dispenzieri A, Moreno-Aspitia A, Suarez GA et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004;104:3400–7. Epub 2004 Jul 27.

    Article  PubMed  CAS  Google Scholar 

  66. Bardwick PZ, Zvaifler NJ, Gill GN et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes: the POEMS syndrome. Medicine 1980;59:311–322.

    Article  PubMed  CAS  Google Scholar 

  67. Nakanishi T, Sobue I, Toyokura Y et al. The Crow–Fukase syndrome: a study of 102 cases in Japan. Neurology 1984;34:712–720.

    PubMed  CAS  Google Scholar 

  68. Miralles GD, O’Fallon J, Talley NJ. Plasma cell dyscrasia with polyneuropathy: the spectrum of POEMS syndrome. N Engl J Med 1992;327:1919–1923.

    PubMed  CAS  Google Scholar 

  69. DeNavasquez S, Treble HA. A case of primary generalized amyloid disease with involvement of the nerves. Brain 1938;61:116–128.

    Article  Google Scholar 

  70. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis and therapy. Mayo Clin Proc 1999;74:490–494.

    PubMed  CAS  Google Scholar 

  71. Kelly JJ, Jr, Kyle RA, O’Brien PC et al. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol 1979;6:1–7.

    Article  PubMed  Google Scholar 

  72. Trotter JL, Engel WE, Ignaczak TF. Amyloidosis with plasma cell dyscrasia: an overlooked cause of adult onset sensorimotor polyneuropathy. Arch Neurol 1947;34:209–214.

    Google Scholar 

  73. Quattrini A, Nemni R, Sferrazza B et al. Amyloid neuropathy simulating lower motor neuron disease. Neurology 1998;51:600–602.

    PubMed  CAS  Google Scholar 

  74. Simmons Z, Blaivas M, Aguilera AJ et al. Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. J Neurol Sci 1993;120:60–63.

    Article  PubMed  CAS  Google Scholar 

  75. Masouye I. Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: an analysis of 100 cases. Am J Dermatopathol 1997;19:41–45.

    Article  PubMed  CAS  Google Scholar 

  76. Gertz MA, Kyle RZ, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991;77:257–262.

    PubMed  CAS  Google Scholar 

  77. Gertz MA, Kyle RA. Amyloidosis: prognosis and treatment. Semin Arthritis Rheum 1994;24:124–138.

    Article  PubMed  CAS  Google Scholar 

  78. Gertz M. Autologous attack on amyloidsis. Mayo Clin Proc 2006;81:874–876.

    Article  PubMed  Google Scholar 

  79. Rajkumar SV, Gertz MA, Kyle RZ. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998;104:232–237.

    Article  PubMed  CAS  Google Scholar 

  80. Rudnicki SA, Harik SI, Dhodapkar M et al. Nervous system dysfunction in Waldenström’s macroglobulinemia: response to treatment. Neurology 1998;51:1210–1213.

    PubMed  CAS  Google Scholar 

  81. Logothetis J, Kennedy WR, Ellington A et al. Cryoglobulinemic neuropathy. Arch Neurol 1968;19:389–397.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. John J. Kelly MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, University of Virginia, Charlottesville, VA

    David Schiff MD

  2. Center for Neuro-Oncology Dana-Farber/Brigham and Women’s Cancer Center and Department of Neurology, Brigham and Women’s Hospital, Boston, MA

    Santosh Kesari MD, PhD  & Patrick Y. Wen MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Kelly, J.J. (2008). Neurologic Complications of Plasma Cell Dyscrasias. In: Schiff, D., Kesari, S., Wen, P.Y. (eds) Cancer Neurology In Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-412-4_31

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-412-4_31

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-983-3

  • Online ISBN: 978-1-59745-412-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation